Indeed, in patients treated with vemurafenib or the combination of dabrafenib + trametinib, a significant decrease of IL-8 mRNA was observed in tumor biopsies collected 10–14 day after the start of therapy with respect to those obtained at baseline [64], while a strong inhibition of IL-8 secretion was evidenced in human melanoma cell lines treated in vitro with either vemurafenib or tramentinib [65]. The gene discussed is CXCL8; the disease is neoplasm.